Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Androgen-insensitive Prostate Cancer”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Ended earlyNCT00634582
What this trial is testing

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Who this might be right for
Metastatic CancerProstate Cancer
Wake Forest University Health Sciences 2
Testing effectiveness (Phase 2)Study completedNCT05848011
What this trial is testing

Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Androgen-Independent Prostatic CancerAndrogen-Independent Prostatic NeoplasmsProstate Cancer Recurrent+6 more
MacroGenics 154
Testing effectiveness (Phase 2)Ended earlyNCT01020305
What this trial is testing

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Who this might be right for
Prostate CancerProstatic NeoplasmsCastrate-resistant Prostate Cancer (CRPC)+3 more
Sandy Srinivas 5
Testing effectiveness (Phase 2)Ended earlyNCT01450683
What this trial is testing

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Who this might be right for
Prostate CancerProstatic NeoplasmsCastrate-resistant Prostate Cancer (CRPC)+3 more
Stanford University 4
Early research (Phase 1)Study completedNCT00629057
What this trial is testing

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

Who this might be right for
Androgen-insensitive Prostate Cancer
Bavarian Nordic 24
Testing effectiveness (Phase 2)Study completedNCT00450619
What this trial is testing

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Study completedNCT01487863
What this trial is testing

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticHormone Refractory Prostate CancerCastration-resistant Prostate Cancer
Dendreon 69
Large-scale testing (Phase 3)Study completedNCT00065442
What this trial is testing

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Who this might be right for
Prostate Cancer
Dendreon 512
Testing effectiveness (Phase 2)Study completedNCT00928174
What this trial is testing

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Queen's Medical Center 27
Testing effectiveness (Phase 2)Study completedNCT00450463
What this trial is testing

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 64
Testing effectiveness (Phase 2)Ended earlyNCT05551117
What this trial is testing

Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Who this might be right for
Castration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more
MacroGenics 192